Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea
The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.
local tumor control (tumor dimensions; secondary complications; visual acuity; survival
histological assessment of the fraction of living cells in eyes requiring secondary enucleation
Hypofractionated linear accelerator radiotherapy
Study Arms / Comparison Groups
Hypofractionated LINAC radiotherapy
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - The initial height of the melanoma is 7 mm or higher. - Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if the central tumor distance to the optic disc and/or the macula is 3 mm or less. - If other forms of conservative treatment of the melanoma are not possible. Exclusion Criteria: - Prior/Concomitant Treatment. - Extrascleral tumor extension is present. - If the presence of neovascular glaucoma is detected before treatment. - If metastasis is detected at baseline. - Previous participation in any study of investigational drugs within 3 month preceding day 0. - Pregnant women are not allowed to participate in the study.
18 Years - N/A
Accepts Healthy Volunteers
Martin Zehetmayer, MD, +431 40400, [email protected]
Medical University of Vienna
Martin Zehetmayer, MD, Principal Investigator, Department of Ophthalmology, Medical University of Vienna, Austria